Analyst consensus rating
Lakewood-Amedex Biotherapeutics Analyst Rating: none
Direct answer
Lakewood-Amedex Biotherapeutics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.50.
Forecast evidence checked November 16, 2026.
Get free Lakewood-Amedex Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.28
- Average price target
- $7.50
- High price target
- $12.00
- Low price target
- $3.00
- Low target gap
- +962.3%
- Target upside
- +2,555.8%
- High target gap
- +4,149.3%
- Target range width
- 3,187%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- November 16, 2026
- Valid through
- November 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lakewood-Amedex Biotherapeutics?
Lakewood-Amedex Biotherapeutics has a verified none consensus. The same dataset has an average price target of $7.50.
How far are Lakewood-Amedex Biotherapeutics's low and high targets from the recorded price?
The low target implies +962.3%, while the high target implies +4,149.3%.
How many analysts are included in Lakewood-Amedex Biotherapeutics's consensus?
The verified consensus includes 2 analysts.
How is Lakewood-Amedex Biotherapeutics's target upside or downside calculated?
The average target of $7.50 is divided by the recorded price of $0.28, then one is subtracted to produce +2,555.8%. This does not guarantee a future return.
When was Lakewood-Amedex Biotherapeutics's analyst forecast verified?
The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.